BTBradley K. Taylor

Bradley K. Taylor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bradley K. Taylor has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Tyler S. Nelson

    University of Florida

    9 shared publications
  • Pranav Prasoon

    Etiologically Elusive Disorders Research Network (EEDRN)

    7 shared publications
  • Renee R. Donahue

    Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Lexington, USA

    7 shared publications
  • Weisi Fu

    Department of Physiology, College of Medicine, University of Kentucky Medical Center, 800 Rose Street, Lexington, KY, 40536-0298, USA

    6 shared publications
  • Paramita Basu

    Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    5 shared publications
  • Pranav Prasoon

    Department of Anesthesiology and Perioperative Medicine, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

    5 shared publications

Latest Publications

  • Open Access

    Parabrachial neuropeptide Y Y1 receptor–expressing neurons govern the sensory dimension of neuropathic pain

    by Heather N. Allen, Tyler S. Nelson, Nitsan Goldstein, Naomi K. Grabus, Adam Brandner, Faheem Hussain, Nina E. Gakii, Albert T. M. Yeung, Logan V. Kirchner, David Hilferty, et al.

    Pain perception involves complex sensory and emotional processes, yet the supraspinal circuits that sustain neuropathic pain remain incompletely understood. Here, we demonstrate that parabrachial nucleus (PBN) neurons expressing the inhibitory G-protein–coupled neuropeptide Y Y1 receptor ( Npy1r ) are critical modulators of neuropathic pain. Approximately 19% of lateral PBN neurons express Npy1r. Stimulus-evoked Fos activation and calcium dynamics of these neurons increases in mice with spared nerve injury (SNI) compared to sham controls. Pharmacological activation of Y1 receptors or chemogenetic inhibition of Npy1r neurons attenuates SNI-induced mechanical and cold allodynia, without altering baseline sensitivity or conditioned place preference (a measure of affective pain). Preemptive ablation of parabrachial Npy1r neurons before SNI delayed the development of neuropathic hypersensitivity. Conversely, repeated chemogenetic activation of Npy1r neurons produced persistent mechanical and cold hypersensitivity in uninjured animals; this outlasted neuronal activation, indicating sufficiency to drive pain-like states. Viral tracing revealed dense Npy1r projections from lateral parabrachial neurons to forebrain regions including the central amygdala, lateral hypothalamus, zona incerta, and ventromedial thalamus, sites implicated in the sensory and affective dimension of pain. These findings demonstrate that Npy1r -expressing PBN neurons selectively regulate the sensory-discriminative component of neuropathic pain and can maintain long-lasting hypersensitivity even in the absence of injury.


  • Open Access

    Dorsal horn DCC amplification loop induced by endplate osteoclasts generates chronic nociplastic low back pain in male mice

    by Dayu Pan, Mengxi Shen, Elizabeth Abatan, Jinjian Zheng, Philip Nasser, Damien M Laudier, Chao Kong, Lei Yan, Zhaozhu Qiu, James C Iatridis, et al.

    Spine degeneration is associated with low back pain (LBP), a major cause of disability and functional decline. However, effective therapies for non-specific LBP remain limited because its underlying mechanisms are poorly understood. Here, we show that spine degeneration induces netrin-1 secretion in porous endplates to activate DCC signaling in dorsal root ganglion (DRG) neurons in both LBP and naturally aged male mice. Conditional loss of netrin-1 in Trap+ osteoclasts, or Dcc in Avil+ DRG neurons reduced spinal hypersensitivity. Importantly, DCC activation induces Src phosphorylation and SNARE complex docking, leading to presynaptic glutamate release in the dorsal horn (DH). Consequently, presynaptic glutamate release induces expression of both netrin-1 and DCC in DH neurons as a form of postsynaptic plasticity that initiates a positive feedback loop to amplify spinal hypersensitivity. Moreover, netrin-1/DCC expression is also amplified in the parabrachial nucleus (PBN) in the brain in both LBP and aged male mice. Thus, osteoclast-derived netrin-1 in porous endplates activates DCC-mediated hypersensitivity in DRG neurons to be further amplified in the DH neurons. These results promote the concept of non-specific LBP as a form of nociplastic pain.

  • Open Access

    EAE models of neuropathic pain in multiple sclerosis do not require pertussis toxin

    by Sydney R. Lamerand, Paramita Basu, Nina E. Gakii, Skyy S. Steber, Bradley K. Taylor

  • Top Cited Papers
    Open Access

    A parabrachial hub for need-state control of enduring pain

    by Nitsan Goldstein, Amadeus Maes, Heather N. Allen, Tyler S. Nelson, Kayla A. Kruger, Morgan Kindel, Albert T. M. Yeung, Nicholas K. Smith, Jamie R. E. Carty, Lavinia Boccia, et al.

    Long-term sustained pain following acute physical injury is a prominent feature of chronic pain conditions1. Populations of neurons that rapidly respond to noxious stimuli or tissue damage have been identified in the spinal cord and several nuclei in the brain2,3,4. Understanding the central mechanisms that signal ongoing sustained pain, including after tissue healing, remains a challenge5. Here we use spatial transcriptomics, neural manipulations, activity recordings and computational modelling to demonstrate that activity in an ensemble of anatomically and molecularly diverse parabrachial neurons that express the neuropeptide Y (NPY) receptor Y1 (Y1R neurons) is increased following injury and predicts functional coping behaviour. Hunger, thirst or predator cues suppressed sustained pain, regardless of the injury type, by inhibiting parabrachial Y1R neurons via the release of NPY. Together, our results demonstrate an endogenous analgesic hub at pain-responsive parabrachial Y1R neurons.


  • Open Access

    Long-lasting and fast methylglyoxal-scavenging peptide CycK(Myr)R4E alleviates chronic pain in type 2 diabetic mice

    by Paramita Basu, Diogo F. S. Santos, Nina Gakii, Margaret R. Gralinski, Ryan B. Griggs, Sebastian Brings, Thomas Fleming, Keiichiro Susuki, Bradley K. Taylor

    Introduction: Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)R4E, and here evaluated its antihyperalgesic efficacy in the db/db mouse model of type II diabetes painful diabetic neuropathy. Objectives: To test the hypothesis that CycK(Myr)R4E can reduce behavioral and molecular signs of painful diabetic neuropathy. Methods: We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal–regulated kinase as a measure of neuronal activity in spinal cord dorsal horn. Results: We report that a single systemic injection of CycK(Myr)R4E (3 mg/kg) reversed heat hypersensitivity. Repeated systemic injection of CycK(Myr)R4E (0.125 mg/kg, 3 times per week, 6–12 weeks of age) prevented heat hypersensitivity and reduced stimulus-evoked phosphorylated extracellular signal–regulated kinase. Conclusion: These studies promote CycK(Myr)R4E as the most promising MG scavenger for the prevention and treatment of hyperalgesia in type 2 diabetic neuropathic pain.


  • Open Access

    The pharmacotherapeutic potential of neuropeptide Y for chronic pain

    by Al A. Nie, Bradley K. Taylor

    Chronic pain is a major medical problem that requires new therapeutic options. Discovered by Victor Mutt in 1982, neuropeptide Y (NPY) is rapidly emerging as a master regulator of pain relief. Genetic knockdown of NPY or pharmacological inhibition of its receptors demonstrates that NPY signaling tonically inhibits indices of chronic inflammatory and neuropathic pain. Primary targets of NPY analgesia include neurons in the dorsal horn of the spinal cord and the parabrachial nucleus of the brain that express the Npy1r (Y1) receptor. NPY signaling is enhanced following injury, and endogenous analgesic synergy between Y1 receptors and mu opioid receptors maintain chronic pain sensitization in a latent state of remission. We propose that disruptions to endogenous NPY analgesia may mediate pathological transitions from acute to chronic pain, which could be treated by CNS administration of Y1 agonists or Npy2r (Y2) agonists or antagonists, depending on the pain state. Chemogenetic manipulations or targeted ablations in rodent models of chronic inflammation or peripheral nerve injury establish that spinal Y1‐interneurons are necessary and sufficient to elicit behavioral signs of both the sensory and affective dimensions of pain. Transcriptomic and in situ hybridization studies revealed three primary subpopulations of spinal Y1‐interneurons that are conserved in higher order mammals, including non‐human primates and humans. Spinally directed (intrathecal) administration of Y1‐selective pharmacological agonists inhibit pronociceptive neurons that co‐express Y1 and gastrin‐releasing peptide to inhibit neuropathic pain. To circumvent highly invasive administration routes, ongoing studies are leveraging the intranasal route for delivery of NPY into the brain.


  • Open Access

    De novo expression of neuropeptide Y in sensory neurons does not contribute to peripheral neuropathic pain

    by A.H. Cooper, A. Nie, N.S. Hedden, H. Herzog, B.K. Taylor

    Nerve damage induces a robust de novo expression of the pain-modulatory peptide neuropeptide Y (NPY) in large-diameter primary afferent neurons that innervate the dorsal horn of the spinal cord and the dorsal column nuclei. To determine whether this functions to modulate peripheral neuropathic pain, we selectively deleted the Npy gene in neurons of the dorsal root ganglion (DRG), without disruption of its expression in brain or dorsal horn neurons. We then subjected sensory neuron-specific NPY deletion mutant mice ( Pirt -NPY) and their wild-type controls to either sham surgery, spared sural nerve injury (SNI) or spared tibial nerve injury (tSNI). Conditional Npy deletion did not change the severity or duration of static mechanical, dynamic mechanical, or cold allodynia in SNI or tSNI models, nor ongoing neuropathic pain as assessed with conditioned place preference to gabapentin. When injected after the resolution of tSNI-induced mechanical hypersensitivity (a latent pain sensitization model of chronic neuropathic pain), the NPY Y1 receptor-specific antagonist BIBO3304 equally reinstated mechanical hypersensitivity in Pirt -NPY mice and their wildtype controls. We conclude that nerve injury-induced upregulation of NPY in sensory neurons does not cause mechanical or cold hypersensitivity or ongoing pain, and that tonic inhibitory control of neuropathic pain by NPY in the spinal cord is mediated by release from dorsal horn interneurons rather than sensory neurons.

  • Neuropeptide Y Y2 Receptors in Sensory Neurons Tonically Suppress Nociception and Itch but Facilitate Postsurgical and Neuropathic Pain Hypersensitivity

    by Paramita Basu, Akshitha Maddula, Tyler S. Nelson, Pranav Prasoon, Michelle K. Winter, Herbert Herzog, Kenneth E. McCarson, Bradley K. Taylor

    Background: Neuropeptide Y (NPY) Y2 receptor (Y2) antagonist BIIE0246 can both inhibit and facilitate nociception. The authors hypothesized that Y2 function depends on inflammation or nerve injury status. Methods: The authors implemented a battery of behavioral tests in mice of both sexes that received (1) no injury; (2) an incision model of postoperative pain; (3) a spared nerve injury model of neuropathic pain; and (4) a latent sensitization model of chronic postsurgical pain. In addition to Y2 gene expression assays, spinal Y2 G-protein coupling was studied with guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding assays. Results: The authors report that intrathecal BIIE0246 increased mechanical and cold hypersensitivity, produced behavioral signs of spontaneous nociception and itch, and produced conditioned place aversion and preference in normal, uninjured mice. BIIE0246 did not change heat hypersensitivity or motor coordination. Conditional (sensory neuron–specific) Y2 deletion prevented BIIE0246-induced mechanical and cold hypersensitivity, nocifensive behaviors, and aversion. Both conditional deletion and pharmacologic blockade of Y2 reduced mechanical and thermal hypersensitivity after incision or nerve injury. SNI did not change the sensitivity of Y2 G-protein coupling with the Y2 agonist peptide YY (3-36) (PYY3-36), but increased the population of Y2 that effectively coupled G-proteins. Intrathecal PYY3-36 failed to reduce spared nerve injury- or incision-induced hypersensitivity in C57BL/6N mice. Incision did not change Npy2r gene expression in dorsal root ganglion. Conclusions: The authors conclude that Y2 at central terminals of primary afferent neurons provides tonic inhibition of mechanical and cold nociception and itch. This switches to the promotion of mechanical and thermal hyperalgesia in models of acute and chronic postsurgical and neuropathic pain, perhaps due to an increase in the population of Y2 that effectively couples to G-proteins. These results support the development of Y2 antagonists for the treatment of chronic postsurgical and neuropathic pain. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New: